Aclaris Therapeutics is a biopharmaceutical company developing novel therapeutic product candidates, including monoclonal and bispecific antibodies targeting TSLP for respiratory and other indications. Rather than commercializing products directly, the company pursues a partnership-dependent business model, licensing its product candidates to third-party pharmaceutical companies and generating revenue through milestone payments and royalties. The company outsources all development and manufacturing activities to contract research organizations and contract manufacturers, relying on regulatory approval from health authorities, adequate third-party payor reimbursement, and international market access to achieve commercial success.